Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

British Journal of Cancer

Volumn 108, Issue 10, 2013, Pages 2039-2044

  Palmieri, C ^a,b   Gojis, O ^b   Rudraraju, B ^a,b   Stamp Vincent, C ^c   Wilson, D ^c   Langdon, S ^c   Gourley, C ^c   Faratian, D ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PAR6 PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR PAX2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR RECEPTOR COACTIVATOR 3; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878570781     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.199     Document Type: Article

References (39)

1. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D (1993) Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 10: 1957-1968.
2. Alkner S, Bendahl PO, Grabau D, Lovgren K, Stål O, Ryden L, Ferno M. Swedish and South-East Swedish Breast Cancer Groups (2010) AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 21: 238-244.
3. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835.
4. Bai J, Uehara Y, Montell DJ (2000) Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Cell 103: 1047-1058.
5. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF (2002) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8: 2233-2239.
6. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10: 7252-7259.
7. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV (2003) Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 91: 596-602.
8. Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M (2008) Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 109: 255-262.
9. Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-Pokora B, Denkert C, Royer HD (2009) Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 69: 2996-3003.
10. Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, Harrison DJ (2011a) Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. Vis Exp 25: e3334.
11. Faratian D, Um I, Wilson DS, Mullen P, Langdon SP, Harrison DJ (2011b) Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. Eur J Cancer 47: 1420-1431.
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v.1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer: Lyon, France (2010).
13. Gojis O, Rudraraju B, Alifrangis C, Krell J, Libalova P, Palmieri C (2010a) The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol 36: 224-229.
14. Gojis O, Rudraraju B, Gudi M, Hogben K, Sousha S, Coombes RC, Cleator S, Palmieri C (2010b) The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol 7: 83-89.
15. Graham AD, Faratian D, Rae F, Thomas JS (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52: 847-855.
16. Hatch KD, Beecham JB, Blessing JA, Creasman WT (1991) Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68: 269-271.
17. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456: 663-666.
18. International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515.
19. Kirkegaard T, McGlynn LM, Campbell FM, Muller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG, Bartlett JM (2007) Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifentreated breast cancer patients. Clin Cancer Res 13: 1405-1411.
20. Labhart P, Karmakar S, Salicru EM, Egan BS, Alexiadis V, O'Malley BW, Smith CL (2005) Identification of target genes in breast cancer cells directly regulated by the SRC-3 AIB1 coactivator. Proc Natl Acad Assoc Sci 102: 1339-1344.
21. Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF, Miller WR (1994a) Growth inhibition of oestrogen receptor positive human ovarian carcinoma by anti-oestrogens in vitro and in vivo. Eur J Cancer 30A: 682-686.
22. Langdon SP, Gabra H, Bartlett JMS, Rabiasz GJ, Hawkins RA, Tesdale AL, Ritchie AA, Miller WR, Smyth JF (1998) Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res 4: 2245-2251.
23. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Tesdale A, Crew AJ, Miller WR, Smyth JF (1990) Estrogen receptor expression and the effects of tamoxifen on the growth of human ovarian carcinoma cell lines Br J Cancer 62: 213-216.
24. Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale A, Smyth JF, Miller WR (1994b) The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 50: 131-135.
25. Langdon SP, Ritchie A, Young K, Crew AJ, Sweeting V, Bramley T, Hawkins RA, Tesdale A, Smyth JF, Miller WR (1993) Contrasting effects of 17 b-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 55: 459-464.
26. Li AJ, Lerner DL, Gapuzan ME, Karlan BY (2005) AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev 14: 2919-2922.
27. Li C, Liang YY, Feng XH, Tsai SY, Tsai MJ, O'Malley BW (2008a) Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol Cell 31: 835-849.
28. Li LB, Louie MC, Chen HW, Zou JX (2008b) Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett 261: 64-73.
29. Liao L, Chen X, Wang S, Parlow AF, Xu J (2008) Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-I) by controlling IGF-binding protein 3 expression. Mol Cell Biol 28: 2460-2469.
30. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B (1996) Tamoxifen in platinum-refractory ovarian cancer: a Gynecology Oncology Group Ancillary Report. Gynecol Oncol 62: 4-6.
31. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18: 106-115.
32. Oh A, List HJ, Reiter R, Mani A, Zhang Y, Gehan E, Wellstein A, Riegel AT (2004) The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 64: 8299-8308.
33. Oh A, List HJ, Reiter R, Mani A, Zhang Y, Gehan E, Wellstein A, Riegel AT (2008) The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 64: 8299-8308.
34. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361.
35. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M, Dimopoulos MA (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66: 112-117.
36. Qin L, Liao L, Redmond A, Young L, Yuan Y, Chen H, O'Malley BW, Xu J (2008) The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 28: 5937-5959.
37. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP (2007) Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-3622.
38. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ (2000) Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin. Cancer Res 6: 1833-1839.
39. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC. Gynecologic Cancer InterGroup (2011) First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 21: 756-762.